Key pharmacokinetic parameters of isepamicin in febrile neutropenic cancer patients and in women with acute pelvic inflammatory disease

Journal of Chemotherapy

Volumn 17, Issue 5, 2005, Pages 521-526

  Yombi, J C ^a   Wallemacq, P ^b   Leal, T ^b   Gala, J L ^c   Vandercam, B ^a,d  

^a Infectious Disease Research Centre   (Belgium)

^b Department of Clinical Chemistry ^*  (Belgium)

^c Defence Laboratories Department   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cancer; Febrile neutropenia; Fever; Isepamicin; Pelvic inflammatory disease; Pharmacokinetics

Indexed keywords

AMIKACIN; AMPICILLIN; CEFTRIAXONE; GENTAMICIN; ISEPAMICIN; NETILMICIN; TINIDAZOLE; TOBRAMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CANCER PATIENT; CELLULITIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; PELVIC INFLAMMATORY DISEASE;

EID: 28144459143     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.5.521     Document Type: Article

References (39)

1. Hare RS, Schaffer TW, Chiu PJS, Sabatelli FJ, El Moss JR, Miller GH. Evaluation of new 1-N-substituted aminoglycosides against strains with known resistance mechanisms. Curr Chemother Infect Dis 1980; l 1: 403-5.
2. Jones RN. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency and spectrum of activity. J Chemother 1995; 7: S7-S16.
3. Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ and the aminoglycoside resistance study groups. The most frequently occurring aminoglycoside resistance mechanisms: combined results of surveys in eight regions of the world. J Chemother 1995; 7: S17-S30.
4. Lin CC, Korduba C, Affrime M, et al. Pharmacokinetics and metabolism of C14-isepamicin in humans following intravenous administration. Antimicrob Agents Chemother 1995; 39:2201-3.
5. Radwanski E, Batra V, Cayen M, et al. Pharrnacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections. Antimicrob Agents Chemother 1997; 41:1794-6.
6. Halstenson CE, Kelloway SJ, Affrime MB, Lin CC, Teal MA, Shapiro BE. Isepamicin disposition in subjects with various degrees of renal function. Antimicrob Agents Chemother 1991; 5 Suppl 2: 2382-7.
7. Uematsu T. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. Int J Clin Pharmacol Ther Toxicol 1993; 31: 606-10.
8. Tod M, Padoin C, Minozzi C, Cougnard J, Petitjean O. Population pharmacokinetic study of isepamicin with intensive care unit patients. Antimicrob Agents Chemother 1996; 40: 983-7.
9. Zeitany RG, El Saghir NS, Santhosh-Kumar CR, Sigmon MA. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990; 34: 702-8.
10. Zaske DE, Cipolle RJ, Strate RG, Dickes WF. Increased gentamicin dosage requirements: rapid elimination in 249 gynecology patients. Am J Obstet Gynecol 1981; 139: 896-900.
11. Leal T, Parez JJ, Vanbinst R, Wallemacq PE. Computerized approach to monitoring aminoglycosides. Clin Chem 1991; 37: 1415-9.
12. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183-95.
13. Watling SM, Dasta JF. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother 1993; 27: 351-7.
14. Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997; 25: 806-11.
15. Dasta JF, Armstang DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16: 327-30.
16. th Interscience Conference of Antimicrobial Agents and Chemotherapy 1996, Sept 15-18, New Orleans.
17. Tod M, Padoin C, Petitjean O. Clinical Pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet 2000; 38: 205-23.
18. Pivot-Dumarest C, Deweerdt C, Troncy J, Sorensen P, Roux D, Maire P. Estimation des paramètres pharmacocinétiques de l'amikacine dans une population de patients neutropéniques en onco-hématologie. Path Biol 1996; 44: 299-305.
19. Kaojarern S, Maoleekoonpairoj S, Atichartakarn V. Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob Agents Chemother 1989; 33: 1406-8.
20. Manny RP, Hutson PR. Aminoglycoside volume of distribution in hematology-oncology patients. Clin Pharm 1986; 5: 626-32.
21. Del Priore G, Jackson-Stone M, Shim EK, Garfinkel J, Eichmann MA, Frederiksen MC. A comparison of once-daily and 8-hour gentamicin dosing in the treatment of postpartum endometritis. Obstet Gynecol 1996; 87:994-1000.
22. Pennington JE, Dale DC, Reynolds HY, MacLowry JD. Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis 1975; 132:270-5.
23. st ed. Chapman & Hall Medical, London, UK. 1997: 25-33.
24. rd ed. Applied Therapeutics, Inc. Vancouver, WA. 1992: 14/2 - 14/11.
25. Singer MA. Of mice and men and elephants: metabolic rate sets glomerular filtration rate. Am J Kid Dis 2001; 37:164-78.
26. Mackowiak PA. Temperature regulation and the pathogenesis of fever. In: Mandell GL, Bennett JE, Dolin R. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Elsevier Churchill Livingstone. Philadelphia, USA. 2005: 703-46.
27. Finley RS, Fortner CL, De Jongh CA, et al. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Antimicrob Agents Chemother 1982; 22:193-7.
28. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-9.
29. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149:443-8.
30. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657-62.
31. The EORTC international antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patient with granulocytopenia N Engl J Med 1987; 317:1692-8.
32. Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monit 1990; 12:427-33.
33. Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-9.
34. McCormack JP, Jewesson PJ. A critical reevaluation of the « Therapeutic Range » of aminoglycosides. Clin Infect Dis 1992; 14:320-39.
35. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
36. Kashuba ADM, Bertino SR Jr, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother 1998;42:1842-4.
37. Amsden GW, Owens RC Jr, Bertino JS Jr. AUIC in humans: a fact-based discussion. Ann Pharmacother 2003; 37 (10): 1518-21.
38. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32 (suppl 1): S39-46.
39. Kiem S, Craig WA. Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoroquinolones against Streptococcus pneumoniae. (abstract 9-492). In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 27-30, 2002